Per WoldOlsen - Gilead Sciences Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
GILD -- USA Stock  

Report: 4th of August 2020  

  Director
Mr. Per WoldOlsen is Independent Director of Gilead Sciences Inc. Mr. WoldOlsen has served as the Chair of Gileads Health Policy Advisory Board since 2007. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle EastAfrica and Worldwide Human Health Marketing for Merck. Mr. WoldOlsen is currently Chairman of the Board of GN Store Nord AS and Oncopeptides AB. In addition, he is the Chairman of the Board of the Medicines for Malaria Venture, a nonprofit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.
Age: 70  Director Since 2010      
650 574-3000  www.gilead.com

Gilead Sciences Management Efficiency

Gilead Sciences has return on total asset (ROA) of 5.36 % which means that it generated profit of $5.36 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 22.29 %, meaning that it created $22.29 on every $100 dollars invested by stockholders. Gilead Sciences management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 9.18. The current year Return on Average Assets is expected to grow to 0.14Gilead Sciences Total Assets Per Share are expected to increase significantly based on the last few years of reporting. The past year's Total Assets Per Share were at 48.68. The current year Asset Turnover is expected to grow to 0.43, whereas Current Assets are expected to decline to about 26.3 B. The current year Tax Liabilities is expected to grow to about 6.6 B, whereas Total Liabilities is expected to decline to about 34.3 B.
The company currently holds 24.1 B in liabilities with Debt to Equity (D/E) ratio of 1.09, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Wendell WeeksMerck Company
2004
Stephen WrightGW Pharmaceuticals Plc
2005
Stephanie BurnsGlaxoSmithKline PLC
2007
Inigo MardonesGrifols S A
2017
Graham ChipchaseAstrazeneca PLC
2019
Sherilyn McCoyAstrazeneca PLC
2017
Nancy AndrewsNovartis AG
2015
Robert KidderMerck Company
2005
Jesse GoodmanGlaxoSmithKline PLC
2017
Roy AndersonGlaxoSmithKline PLC
2007
Mary BeckerleJohnson Johnson
2015
Urs RohnerGlaxoSmithKline PLC
2015
Rudolph MarkhamAstrazeneca PLC
2019
Steven MayerGrifols S A
2016
Togo WestBristol Myers Squibb
2015
Bruce BurlingtonAstrazeneca PLC
2010
Laurie GlimcherBristol Myers Squibb
N/A
Jackson TaiEli Lilly And
2013
Vivienne CoxGlaxoSmithKline PLC
2017
Matthew EmmensBristol Myers Squibb
2017
Shriti VaderaAstrazeneca PLC
2011

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Carla Hills, Independent Director
John Cogan, Lead Independent Director
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page